Plexxikon Inc. Kathleen Sereda Glaub, 510-647-4009 President kglaub@plexxikon.com or For Plexxikon Inc. Jennifer Cook Williams, 360-668-3701 jennifer@cwcomm.org Plexxikon Inc. today announced that it has initiated a Phase 1 human clinical trial for PLX5568, a novel kinase inhibitor targeted for the treatment of at least two major indications with unmet medical needs: pain as well as
Plexxikon initiates Phase 1 trial for PLX5568